Shrividya Iyer
- Pulmonary and Respiratory Medicine top 0.5%
- Oncology top 0.5%
- Cancer Research top 2%
- Molecular Biology top 10%
- Surgery top 5%
- Co-authors
- Arlene ReismanKeith D. WilnerFiona BlackhallBenjamin SolomonYi‐Long WuTony MokDong‐Wan KimEnriqueta Felip
- Topics
- Advanced Breast Cancer Therapies (24 papers)Lung Cancer Treatments and Mutations (19 papers)HER2/EGFR in Cancer Research (13 papers)
- Partner nations
- United StatesUnited KingdomSouth Korea
In The Last Decade
Shrividya Iyer
75 papers receiving 4.7k citations
Hit Papers
Peers
Comparison fields: 5 of 113
- Pulmonary and Respiratory Medicine 3.5k
- Oncology 3.0k
- Cancer Research 1.0k
- Molecular Biology 818
- Surgery 578
Countries citing papers authored by Shrividya Iyer
This map shows the geographic impact of Shrividya Iyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shrividya Iyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shrividya Iyer more than expected).
Fields of papers citing papers by Shrividya Iyer
This network shows the impact of papers produced by Shrividya Iyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shrividya Iyer. The network helps show where Shrividya Iyer may publish in the future.
Co-authorship network of co-authors of Shrividya Iyer
This figure shows the co-authorship network connecting the top 25 collaborators of Shrividya Iyer. A scholar is included among the top collaborators of Shrividya Iyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shrividya Iyer. Shrividya Iyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 3 | |
| 3 | Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-upbreakdown → | 286 |
| 4 | 2 | |
| 5 | 54 | |
| 6 | 14 | |
| 7 | 114 | |
| 8 | 2 | |
| 9 | 3 | |
| 10 | 6 | |
| 11 | 2 | |
| 12 | 3 | |
| 13 | 1 | |
| 14 | 165 | |
| 15 | 10 | |
| 16 | 36 | |
| 17 | 118 | |
| 18 | 22 | |
| 19 | 255 | |
| 20 | 17 |
About Shrividya Iyer
Shrividya Iyer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Family Practice, having authored 76 papers that have together received 4.8k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (24 papers), Lung Cancer Treatments and Mutations (19 papers) and HER2/EGFR in Cancer Research (13 papers). The work is most often cited by research in Oncology (3.0k citations), Pulmonary and Respiratory Medicine (3.5k citations) and Cancer Research (1.0k citations). Shrividya Iyer has collaborated with scholars based in United States, United Kingdom and South Korea. Frequent co-authors include Arlene Reisman, Keith D. Wilner, Fiona Blackhall, Benjamin Solomon, Yi‐Long Wu, Tony Mok, Dong‐Wan Kim, Enriqueta Felip, Jolanda Paolini and Tarek Mekhail. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.